Question on F&A for company without NICRA (R21)
Caroline Leopold
(28 Jul 2014 09:10 EST)
|
Re: Question on F&A for company without NICRA (R21)
Moise, Jessica
(28 Jul 2014 10:21 EST)
|
Re: Question on F&A for company without NICRA (R21)
Caroline Leopold
(28 Jul 2014 12:44 EST)
|
Re: Question on F&A for company without NICRA (R21) Lawrence Waxler (28 Jul 2014 10:44 EST)
|
Re: Question on F&A for company without NICRA (R21)
Michael Spires
(28 Jul 2014 12:03 EST)
|
Re: Question on F&A for company without NICRA (R21)
Caroline Leopold
(28 Jul 2014 12:59 EST)
|
Re: Question on F&A for company without NICRA (R21) Lawrence Waxler 28 Jul 2014 10:44 EST
Caroline, Under the new OMNI Circular, the Federal government is allowing a 10% rate for any agency with no negotiated rate. If the company wants anything difference/higher, given that the new regs are not final from each agencies perspective and won't be until December, you should probably contact the NIH program officer to get a read on what they will allow or what process they might suggest. Larry ~~~~~~~~~~~~~~~~~~~~~~~ Larry Waxler, Director Office of Sponsored Programs University of Southern Maine 1 Chamberlain Avenue P.O. Box 9300 Portland, ME 04104-9300 Telephone: 207-780-4413 Telefax: 207-780-4927 >>> Caroline Leopold <xxxxxx@LEOPOLDGRANTS.COM> 7/28/2014 10:10 AM >>> I am providing pre-award consulting with a digital health company who has partnered with a university PI to submit an R21 for NIH's October deadline. The company's role is substantial and wants to be a consortium partner. Multiple staff at the company will serve as key personnel and are allocated effort in the budget. However, the company does not have a negotiated indirect cost rate agreement (NICRA). I am more familiar with the F&A rules of SBIR/STTR in regards to companies. I have reviewed the NIH FAQ at: http://oalm.od.nih.gov/IndirectCostsFAQ#processstart It appears as if the company can add a reasonable indirect rate into the NIH grant application and then negotiate with the NIH if there is a strong possibility of an award. I fear that I am overly optimistic and misreading the guidelines. That is why I am turning the experts here at RESADM-L. Any guidance on or offlist would be greatly appreciated. Thank you so much. Best Regards, Caroline -- Caroline Leopold, GPC Grants Consultant and Medical Writer Leopold Grants Consulting xxxxxx@leopoldgrants.com LinkedIn Profile <http://www.linkedin.com/in/cleopold/> ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.healthresearch.org (click on the "LISTSERV" link in the upper right corner) A link directly to helpful tips: http://tinyurl.com/resadm-l-help ====================================================================== ====================================================================== Instructions on how to use the RESADM-L Mailing List, including subscription information and a web-searchable archive, are available via our web site at http://www.healthresearch.org (click on the "LISTSERV" link in the upper right corner) A link directly to helpful tips: http://tinyurl.com/resadm-l-help ======================================================================